

Good Clinical Practice Day 2

James Pound

Deputy Director, Standards & Compliance
Healthcare Quality and Access
MHRA

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop
February 13, 2024



Medicines & Healthcare products
Regulatory Agency



Health
Canada

Santé
Canada



Welcome to Day 2

8:30 – 8:40

Day Two Welcome

Forest "Ray" Ford, PharmD, BCPS
*Captain | United States Public Health Service (USPHS)
Pharmacist | Small Business and Industry Assistance (SBIA)
Division of Drug Information (DDI) Office of Communications (OCOMM)
Center for Drug Evaluation and Research (CDER)*

8:40 – 8:55

Opening Remarks & Keynote Address

James Pound, BSc, CChem
*Deputy Director | Standards & Compliance
MHRA*

9:00 – 10:00

Session 1- Sponsor Oversight in Clinical Trials

Moderator: **Adil Nashed, BVSc, DHMS** | *Compliance Specialist
ROEB | HC*

- Discuss sponsor role and oversight responsibilities in global clinical trials, including those trials incorporating novel designs, operational approaches, and data sources
- Highlight the expanding use of 3rd parties and service providers performing clinical trial-related activities
- Discuss risk proportionate sponsor oversight measures that focus on what is important to ensure reliable trial results, trial participant's safety, and appropriate decision making

Adil Nashed, BVSc., DHMS
Compliance Specialist | ROEB | HC

Barbara Wright, BA
*Foreign Cadre Director | Foreign BIMO Cadre
FDA | ORA*

Jason Wakelin-Smith, BSc
*Expert GCP Inspector and
Head of the Compliance Expert Circle | MHRA*

10:00 – 10:20: BREAK

10:25 – 11:25

Session 2 – Clinical Trials Post-Pandemic – Positive Disruption to Established Ways of Working?

Moderator: **Iram Hassan, PhD** | *LCDR | USPHS | OSI | GCOB |
FDA*

- Discuss changes in the conduct of clinical trials and inspection activities post-pandemic
- Discuss the adoption of regulatory flexibilities into routine practice
- Insights from inspections on new approaches to clinical trial conduct

Jason Wakelin-Smith, BSc
*Expert GCP Inspector and
Head of the Compliance Expert Circle | MHRA*

Jennifer Evans, BSc
Compliance Specialist | ROEB | HC

Richard Berning
Foreign BIMO Cadre | ORA | FDA

Day 2

Oversight



Day 2

Post pandemic



Day 2

Collaboration





Overview

Today's Agenda:

- Sponsor Oversight
- Clinical Trials Post Pandemic
- The Future of GCP Inspections
- Regulatory Updates and Collaboration
- Panel Discussion



**Please enjoy day two of our
symposium!**



MHRA Copyright information

© **Crown copyright 2024**

Produced by the Medicines and Healthcare products Regulatory Agency

You may re-use this information (excluding logos) with the permission from the Medicines and Healthcare products Regulatory Agency, under a Delegation of Authority. To view the guideline, visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information> or email: copyright@mhra.gov.uk.

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

The names, images and logos identifying the Medicines and Healthcare products Regulatory Agency are proprietary marks. All the Agency's logos are registered Trademarks and cannot be used without the Agency's explicit permission.